KY-02327 acetate

KY-02327 醋酸盐

KY-02327 acetate

K658920-5mg

5mg

≥99%

2-8°C储存,避光,干燥

冰袋运输

KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation. Appearance:Solid In Vitro:KY-02327 (1-10 μM; 2 days; MC3T3E1 cells, a murine pre-osteoblast cell line) acetate increases β-catenin protein level together with Runx2 and accumulated nuclear β-catenin in a dose-dependent manner. KY-02327 (1-10 μM) acetate increases the mRNA lev In Vivo:KY-02327 (20mg/kg; p.o.; 5 sequential days per week for 4 weeks) acetate successfully rescues bone loss in the ovariectomized (OVX) mouse model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Biological Activity:KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation.

C22H31N3O6

433.5 g/mol

O=C(C(N1CC(NCCN2CCCCC2)=O)=CC3=C1C=CC(O)=C3)OCC.CC(O)=O

DMSO : 50 mg/mL (115.34 mM; ultrasonic and warming and heat to 60°C)